TapewireFind a company

person · Reporting owner

Wu Xiaobin

Disclosed activity across 1 company

Tapewire entity
18998
SEC CIK
0001739452

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BeOne Medicines Ltd.ONC · Entity 2168President and COOAugust 25, 2026August 27, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BeOne Medicines Ltd.

Report date August 25, 2026 · Filed August 27, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
American Depositary SharesSEC Table I · non-derivativeDirect0 Reported balance After 2026-08-25 transaction · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · 2026-08-25 · Sale · Disposed 280 · Balance 0

F1: Each American Depositary Share represents 13 Ordinary Shares.

F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025.

American Depositary SharesSEC Table I · non-derivativeDirect12,365 Reported balance Holding disclosure · report date 2026-08-25 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 12,365

F1: Each American Depositary Share represents 13 Ordinary Shares.

Ordinary SharesSEC Table I · non-derivativeDirect1,270,084 Reported balance Holding disclosure · report date 2026-08-25 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 1,270,084

American Depositary SharesSEC Table I · non-derivativeIndirectBy Wife4,000 Reported balance Holding disclosure · report date 2026-08-25 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 4,000

F1: Each American Depositary Share represents 13 Ordinary Shares.

Filing footnotes · ownership attribution and instrument terms

F1: Each American Depositary Share represents 13 Ordinary Shares.

F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 16, 2025 Filed Jun 18, 2025 21:08 UTC BeOne Medicines Ltd. ONC · Entity 2168 SaleAmerican Depositary Shares 1,443 $265.47 $383,072.49
Disclosure

SEC source: 0001651308-25-000112 · wk-form4_1750280880.xml · nonDerivative · entry 4

Wu Xiaobin · CIK 0001739452 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 730

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.21 to $266.01, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
June 10, 2025 Filed Jun 12, 2025 21:42 UTC BeOne Medicines Ltd. ONC · Entity 2168 GrantShare Option (Right to Buy) · Derivative 232,245 $0.00 Strike: $20.26 $0.00
Disclosure

SEC source: 0001651308-25-000106 · wk-form4_1749764515.xml · derivative · entry 4

Wu Xiaobin · CIK 0001739452 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 232,245

Underlying: Ordinary Shares · 232,245 shares

Expires 2035-06-09

F3 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F3 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F4 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 10, 2025 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Read SEC document
June 10, 2025 Filed Jun 12, 2025 21:42 UTC BeOne Medicines Ltd. ONC · Entity 2168 GrantOrdinary Shares 123,370 $0.00 $0.00
Disclosure

SEC source: 0001651308-25-000106 · wk-form4_1749764515.xml · nonDerivative · entry 1

Wu Xiaobin · CIK 0001739452 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,274,296

F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 10, 2025, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Read SEC document
June 06, 2025 Filed Jun 10, 2025 20:55 UTC BeOne Medicines Ltd. ONC · Entity 2168 SaleAmerican Depositary Shares 234 $255.77 $59,850.02
Disclosure

SEC source: 0001651308-25-000101 · wk-form4_1749588905.xml · nonDerivative · entry 8

Wu Xiaobin · CIK 0001739452 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $255.67 to $255.8887, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
June 06, 2025 Filed Jun 10, 2025 20:55 UTC BeOne Medicines Ltd. ONC · Entity 2168 SaleAmerican Depositary Shares 400 $255.31 $102,122.00
Disclosure

SEC source: 0001651308-25-000101 · wk-form4_1749588905.xml · nonDerivative · entry 7

Wu Xiaobin · CIK 0001739452 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 234

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $254.60 to $255.59, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
June 06, 2025 Filed Jun 10, 2025 20:55 UTC BeOne Medicines Ltd. ONC · Entity 2168 SaleAmerican Depositary Shares 400 $253.50 $101,399.00
Disclosure

SEC source: 0001651308-25-000101 · wk-form4_1749588905.xml · nonDerivative · entry 6

Wu Xiaobin · CIK 0001739452 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 634

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $253.31 to $253.81, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
June 06, 2025 Filed Jun 10, 2025 20:55 UTC BeOne Medicines Ltd. ONC · Entity 2168 SaleAmerican Depositary Shares 500 $251.85 $125,926.00
Disclosure

SEC source: 0001651308-25-000101 · wk-form4_1749588905.xml · nonDerivative · entry 5

Wu Xiaobin · CIK 0001739452 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,034

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $251.585 to $252.14, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
June 06, 2025 Filed Jun 10, 2025 20:55 UTC BeOne Medicines Ltd. ONC · Entity 2168 SaleAmerican Depositary Shares 400 $250.74 $100,294.00
Disclosure

SEC source: 0001651308-25-000101 · wk-form4_1749588905.xml · nonDerivative · entry 4

Wu Xiaobin · CIK 0001739452 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,534

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $250.56 to $251.26, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 21:04 UTC BeOne Medicines Ltd. BGNE · Entity 2168 Exercise / conversionShare Option (Right to Buy) · Derivative 460,772 $0.00 Strike: $13.42 $0.00
Disclosure

SEC source: 0001651308-25-000053 · wk-form4_1743714287.xml · derivative · entry 11

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 296,049

Underlying: Ordinary Shares · 460,772 shares

Expires 2030-06-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares.

F10 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 17, 2021 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 21:04 UTC BeOne Medicines Ltd. BGNE · Entity 2168 Exercise / conversionShare Option (Right to Buy) · Derivative 214,201 $0.00 Strike: $9.23 $0.00
Disclosure

SEC source: 0001651308-25-000053 · wk-form4_1743714287.xml · derivative · entry 10

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 214,201 shares

Expires 2029-06-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares.

F9 · derivative.exercise_date: These securities vest over a five-year period as follows: 20% on April 30, 2019, and the remaining in 48 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 21:04 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 5,083 $283.79 $1,442,520.84
Disclosure

SEC source: 0001651308-25-000053 · wk-form4_1743714287.xml · nonDerivative · entry 9

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $283.12 to $284.10, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 21:04 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 12,221 $282.76 $3,455,640.51
Disclosure

SEC source: 0001651308-25-000053 · wk-form4_1743714287.xml · nonDerivative · entry 8

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,083

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $282.03 to $283.01, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 21:04 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 6,364 $281.67 $1,792,570.79
Disclosure

SEC source: 0001651308-25-000053 · wk-form4_1743714287.xml · nonDerivative · entry 7

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,304

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.01 to $282.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 21:04 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 28,253 $280.31 $7,919,637.98
Disclosure

SEC source: 0001651308-25-000053 · wk-form4_1743714287.xml · nonDerivative · entry 6

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,668

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $280.00 to $280.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 21:04 UTC BeOne Medicines Ltd. BGNE · Entity 2168 Exercise / conversionAmerican Depositary Shares 35,444 $174.43 $6,182,496.92
Disclosure

SEC source: 0001651308-25-000053 · wk-form4_1743714287.xml · nonDerivative · entry 5

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,921

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 21:04 UTC BeOne Medicines Ltd. BGNE · Entity 2168 Exercise / conversionAmerican Depositary Shares 16,477 $119.96 $1,976,580.92
Disclosure

SEC source: 0001651308-25-000053 · wk-form4_1743714287.xml · nonDerivative · entry 4

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,477

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

Read SEC document
March 14, 2025 Filed Mar 18, 2025 20:51 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleRMB Shares 0 $0.00 $0.00
Disclosure

SEC source: 0001651308-25-000051 · wk-form4_1742331075.xml · nonDerivative · entry 4

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F2 · security: The term "RMB Shares" is used herein to represent the ordinary shares, par value $0.0001 per share, of the Issuer, issued directly by the Issuer in the Issuer's initial public offering on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange (the "STAR Offering"), to permitted investors in Renminbi ("RMB") within the People's Republic of China ("PRC") in accordance with the rules of the STAR Market.

F3 · shares: The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924).

F4 · shares: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, contributed RMB15 million to the RMB Shares Employee Participation Plan upon the establishment of the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose.

F5 · shares: The Reporting Person disposed of a portion of his economic interest in the RMB Shares Employee Participation Plan and expects to receive net proceeds of approximately RMB7,657,022 (or US$1,057,600 based on an exchange rate of US$1.00 = RMB7.24) for such disposal.

F5 · price: The Reporting Person disposed of a portion of his economic interest in the RMB Shares Employee Participation Plan and expects to receive net proceeds of approximately RMB7,657,022 (or US$1,057,600 based on an exchange rate of US$1.00 = RMB7.24) for such disposal.

F3 · balance_after: The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924).

F4 · balance_after: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, contributed RMB15 million to the RMB Shares Employee Participation Plan upon the establishment of the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose.

F4 · ownership.nature: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, contributed RMB15 million to the RMB Shares Employee Participation Plan upon the establishment of the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose.

Read SEC document
March 05, 2025 Filed Mar 8, 2025 00:24 UTC BeOne Medicines Ltd. BGNE · Entity 2168 Exercise / conversionShare Option (Right to Buy) · Derivative 583,349 $0.00 Strike: $9.23 $0.00
Disclosure

SEC source: 0001651308-25-000046 · wk-form4_1741393434.xml · derivative · entry 12

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 214,201

Underlying: Ordinary Shares · 583,349 shares

Expires 2029-06-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares.

F11 · derivative.exercise_date: These securities vest over a five-year period as follows: 20% on April 30, 2019, and the remaining in 48 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events.

Read SEC document
March 05, 2025 Filed Mar 8, 2025 00:24 UTC BeOne Medicines Ltd. BGNE · Entity 2168 Exercise / conversionShare Option (Right to Buy) · Derivative 91,624 $0.00 Strike: $13.05 $0.00
Disclosure

SEC source: 0001651308-25-000046 · wk-form4_1741393434.xml · derivative · entry 11

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2

Underlying: Ordinary Shares · 91,624 shares

Expires 2028-04-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares.

F11 · derivative.exercise_date: These securities vest over a five-year period as follows: 20% on April 30, 2019, and the remaining in 48 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events.

Read SEC document
March 05, 2025 Filed Mar 8, 2025 00:24 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 200 $263.00 $52,600.00
Disclosure

SEC source: 0001651308-25-000046 · wk-form4_1741393434.xml · nonDerivative · entry 10

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024.

Read SEC document
March 05, 2025 Filed Mar 8, 2025 00:24 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 22,537 $262.51 $5,916,235.20
Disclosure

SEC source: 0001651308-25-000046 · wk-form4_1741393434.xml · nonDerivative · entry 9

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 200

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $262.00 to $262.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
March 05, 2025 Filed Mar 8, 2025 00:24 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 11,360 $261.61 $2,971,881.65
Disclosure

SEC source: 0001651308-25-000046 · wk-form4_1741393434.xml · nonDerivative · entry 8

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,737

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.00 to $261.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
March 05, 2025 Filed Mar 8, 2025 00:24 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 17,824 $260.39 $4,641,187.80
Disclosure

SEC source: 0001651308-25-000046 · wk-form4_1741393434.xml · nonDerivative · entry 7

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,097

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.00 to $260.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
March 05, 2025 Filed Mar 8, 2025 00:24 UTC BeOne Medicines Ltd. BGNE · Entity 2168 Exercise / conversionAmerican Depositary Shares 44,873 $119.96 $5,382,965.08
Disclosure

SEC source: 0001651308-25-000046 · wk-form4_1741393434.xml · nonDerivative · entry 6

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,921

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

Read SEC document
March 05, 2025 Filed Mar 8, 2025 00:24 UTC BeOne Medicines Ltd. BGNE · Entity 2168 Exercise / conversionAmerican Depositary Shares 7,048 $169.65 $1,195,693.20
Disclosure

SEC source: 0001651308-25-000046 · wk-form4_1741393434.xml · nonDerivative · entry 5

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,048

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

Read SEC document
March 05, 2025 Filed Mar 8, 2025 00:24 UTC BeOne Medicines Ltd. BGNE · Entity 2168 GrantOrdinary Shares 103,883 $0.00 $0.00
Disclosure

SEC source: 0001651308-25-000046 · wk-form4_1741393434.xml · nonDerivative · entry 1

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,175,210

F1 · shares: Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2027, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested securities are subject to accelerated vesting upon certain termination events.

Read SEC document
February 28, 2025 Filed Mar 4, 2025 22:17 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleRMB Shares 0 $0.00 $0.00
Disclosure

SEC source: 0001651308-25-000038 · wk-form4_1741126625.xml · nonDerivative · entry 4

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F2 · security: The term "RMB Shares" is used herein to represent the ordinary shares, par value $0.0001 per share, of the Issuer, issued directly by the Issuer in the Issuer's initial public offering on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange (the "STAR Offering"), to permitted investors in Renminbi ("RMB") within the People's Republic of China ("PRC") in accordance with the rules of the STAR Market.

F3 · shares: The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924).

F4 · shares: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, contributed RMB15 million to the RMB Shares Employee Participation Plan upon the establishment of the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose.

F5 · shares: The Reporting Person disposed of a portion of his economic interest in the RMB Shares Employee Participation Plan and expects to receive net proceeds of approximately RMB8,445,965 (or US$1,161,756 based on an exchange rate of US$1.00 = RMB7.27) for such disposal.

F5 · price: The Reporting Person disposed of a portion of his economic interest in the RMB Shares Employee Participation Plan and expects to receive net proceeds of approximately RMB8,445,965 (or US$1,161,756 based on an exchange rate of US$1.00 = RMB7.27) for such disposal.

F3 · balance_after: The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924).

F4 · balance_after: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, contributed RMB15 million to the RMB Shares Employee Participation Plan upon the establishment of the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose.

F4 · ownership.nature: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, contributed RMB15 million to the RMB Shares Employee Participation Plan upon the establishment of the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose.

Read SEC document
February 20, 2025 Filed Feb 20, 2025 23:12 UTC BeOne Medicines Ltd. BGNE · Entity 2168 Exercise / conversionShare Option (Right to Buy) · Derivative 276,471 $0.00 Strike: $13.05 $0.00
Disclosure

SEC source: 0001651308-25-000018 · wk-form4_1740093141.xml · derivative · entry 12

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 91,626

Underlying: Ordinary Shares · 276,471 shares

Expires 2028-04-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares.

F11 · derivative.exercise_date: These securities vest over a five-year period as follows: 20% on April 30, 2019, and the remaining in 48 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events.

Read SEC document
February 20, 2025 Filed Feb 20, 2025 23:12 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 21,267 $240.07 $5,105,513.40
Disclosure

SEC source: 0001651308-25-000018 · wk-form4_1740093141.xml · nonDerivative · entry 10

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.00 to $240.50, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
February 20, 2025 Filed Feb 20, 2025 23:12 UTC BeOne Medicines Ltd. BGNE · Entity 2168 Exercise / conversionAmerican Depositary Shares 21,267 $169.65 $3,607,946.55
Disclosure

SEC source: 0001651308-25-000018 · wk-form4_1740093141.xml · nonDerivative · entry 9

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,267

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 23:12 UTC BeOne Medicines Ltd. BGNE · Entity 2168 Exercise / conversionShare Option (Right to Buy) · Derivative 398,502 $0.00 Strike: $13.05 $0.00
Disclosure

SEC source: 0001651308-25-000018 · wk-form4_1740093141.xml · derivative · entry 11

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 368,097

Underlying: Ordinary Shares · 398,502 shares

Expires 2028-04-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares.

F11 · derivative.exercise_date: These securities vest over a five-year period as follows: 20% on April 30, 2019, and the remaining in 48 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 23:12 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 3,159 $242.08 $764,728.82
Disclosure

SEC source: 0001651308-25-000018 · wk-form4_1740093141.xml · nonDerivative · entry 8

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.00 to $242.28, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 23:12 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 7,919 $241.26 $1,910,558.53
Disclosure

SEC source: 0001651308-25-000018 · wk-form4_1740093141.xml · nonDerivative · entry 7

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,159

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $241.00 to $241.96, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 23:12 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 19,576 $240.31 $4,704,243.96
Disclosure

SEC source: 0001651308-25-000018 · wk-form4_1740093141.xml · nonDerivative · entry 6

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,078

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.00 to $240.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 23:12 UTC BeOne Medicines Ltd. BGNE · Entity 2168 Exercise / conversionAmerican Depositary Shares 30,654 $169.65 $5,200,451.10
Disclosure

SEC source: 0001651308-25-000018 · wk-form4_1740093141.xml · nonDerivative · entry 5

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,654

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

Read SEC document
December 06, 2024 Filed Dec 11, 2024 01:19 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleRMB Shares 0 $0.00 $0.00
Disclosure

SEC source: 0001651308-24-000165 · wk-form4_1733879987.xml · nonDerivative · entry 4

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F2 · security: The term "RMB Shares" is used herein to represent the ordinary shares, par value $0.0001 per share, of the Issuer, issued directly by the Issuer in the Issuer's initial public offering on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange (the "STAR Offering"), to permitted investors in Renminbi ("RMB") within the People's Republic of China ("PRC") in accordance with the rules of the STAR Market.

F3 · shares: The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924).

F4 · shares: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, contributed RMB15 million to the RMB Shares Employee Participation Plan upon the establishment of the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose.

F5 · shares: The Reporting Person disposed of a portion of his economic interest in the RMB Shares Employee Participation Plan and expects to receive net proceeds of approximately RMB878,900 (or US$120,894 based on an exchange rate of US$1.00 = RMB7.27) for such disposal.

F5 · price: The Reporting Person disposed of a portion of his economic interest in the RMB Shares Employee Participation Plan and expects to receive net proceeds of approximately RMB878,900 (or US$120,894 based on an exchange rate of US$1.00 = RMB7.27) for such disposal.

F3 · balance_after: The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924).

F4 · balance_after: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, contributed RMB15 million to the RMB Shares Employee Participation Plan upon the establishment of the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose.

F4 · ownership.nature: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, contributed RMB15 million to the RMB Shares Employee Participation Plan upon the establishment of the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose.

Read SEC document
September 19, 2024 Filed Sep 19, 2024 21:25 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 4,500 $200.14 $900,614.70
Disclosure

SEC source: 0001651308-24-000115 · wk-form4_1726781110.xml · nonDerivative · entry 6

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.00 to $200.85, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
September 17, 2024 Filed Sep 19, 2024 21:25 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 500 $200.00 $100,000.00
Disclosure

SEC source: 0001651308-24-000115 · wk-form4_1726781110.xml · nonDerivative · entry 5

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,500

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024.

Read SEC document
September 03, 2024 Filed Sep 5, 2024 21:41 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 274 $192.04 $52,619.92
Disclosure

SEC source: 0001651308-24-000112 · wk-form4_1725572488.xml · nonDerivative · entry 9

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $191.89 to $192.17, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
September 03, 2024 Filed Sep 5, 2024 21:41 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 700 $191.20 $133,843.43
Disclosure

SEC source: 0001651308-24-000112 · wk-form4_1725572488.xml · nonDerivative · entry 8

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 274

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $190.86 to $191.57, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
September 03, 2024 Filed Sep 5, 2024 21:41 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 2,275 $190.29 $432,908.61
Disclosure

SEC source: 0001651308-24-000112 · wk-form4_1725572488.xml · nonDerivative · entry 7

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 974

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.85 to $190.82, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
September 03, 2024 Filed Sep 5, 2024 21:41 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 275 $188.97 $51,967.74
Disclosure

SEC source: 0001651308-24-000112 · wk-form4_1725572488.xml · nonDerivative · entry 6

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,249

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.85 to $189.81, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
September 03, 2024 Filed Sep 5, 2024 21:41 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 2,032 $188.16 $382,337.06
Disclosure

SEC source: 0001651308-24-000112 · wk-form4_1725572488.xml · nonDerivative · entry 5

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,524

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $187.78 to $188.64, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
June 24, 2024 Filed Jun 26, 2024 21:24 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 23 $161.27 $3,709.21
Disclosure

SEC source: 0001651308-24-000077 · wk-form4_1719437065.xml · nonDerivative · entry 7

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

Read SEC document
June 24, 2024 Filed Jun 26, 2024 21:24 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 400 $160.38 $64,151.28
Disclosure

SEC source: 0001651308-24-000077 · wk-form4_1719437065.xml · nonDerivative · entry 6

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.16 to $161.0328, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
June 24, 2024 Filed Jun 26, 2024 21:24 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 1,036 $159.53 $165,272.77
Disclosure

SEC source: 0001651308-24-000077 · wk-form4_1719437065.xml · nonDerivative · entry 5

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 423

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.13 to $159.795, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
June 18, 2024 Filed Jun 20, 2024 21:25 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 300 $156.80 $47,040.99
Disclosure

SEC source: 0001651308-24-000072 · wk-form4_1718918703.xml · nonDerivative · entry 9

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

F10 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.61 to $156.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
June 18, 2024 Filed Jun 20, 2024 21:25 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 300 $155.15 $46,544.76
Disclosure

SEC source: 0001651308-24-000072 · wk-form4_1718918703.xml · nonDerivative · entry 8

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

F10 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.09 to $155.23, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
June 18, 2024 Filed Jun 20, 2024 21:25 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 906 $154.17 $139,680.01
Disclosure

SEC source: 0001651308-24-000072 · wk-form4_1718918703.xml · nonDerivative · entry 7

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 600

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

F10 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.00 to $154.42, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
June 18, 2024 Filed Jun 20, 2024 21:25 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 1,121 $153.66 $172,250.06
Disclosure

SEC source: 0001651308-24-000072 · wk-form4_1718918703.xml · nonDerivative · entry 6

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,506

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

F8 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 17, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.47 to $153.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.